A Phase Iii, Double-Blind, Randomized Study Of Nivolumab (Nivo) And Ipilimumab (Ipi), Nivo Monotherapy Or Placebo Plus Transarterial Chemoembolization (Tace) In Patients With Intermediate-Stage Hepatocellular Carcinoma (Hcc).

Bruno Sangro,James J. Harding,Matthew Johnson,Daniel H. Palmer,Julien Edeline,Ghassan K. Abou-Alfa,Ann-Lii Cheng,Thomas Decaens,Anthony B. El-Khoueiry,Richard S. Finn,Peter R. Galle,Joong-Won Park,Thomas Yau,Damir Begic,Yun Shen,Jaclyn Neely, Ashwin Reddy Sama,Masatoshi Kudo

JOURNAL OF CLINICAL ONCOLOGY（2021）

引用 11|浏览22

暂无评分

摘要

TPS349Background: TACE is the most widely used locoregional therapy recommended for patients with intermediate-stage HCC (Barcelona Clinic Liver Cancer stage B). Despite the significant tumor respo...

查看译文

关键词

hepatocellular carcinoma,nivolumab monotherapy,transarterial chemoembolization,double-blind,intermediate-stage

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要